Fatty Fish Intake Decreases Lipids Related to Inflammation and Insulin Signaling—A Lipidomics Approach by Lankinen, Maria et al.
Fatty Fish Intake Decreases Lipids Related to
Inflammation and Insulin Signaling—A Lipidomics
Approach
Maria Lankinen
1,2, Ursula Schwab
2,3, Arja Erkkila ¨
4, Tuulikki Seppa ¨nen-Laakso
1, Marja-Leena Hannila
5,
Hanna Mussalo
6, Seppo Lehto
3, Matti Uusitupa
2, Helena Gylling
2,3, Matej Ores ˇic ˇ
1*
1VTT Technical Research Centre of Finland, Espoo, Finland, 2Department of Clinical Nutrition, School of Public Health and Clinical Nutrition, University of Kuopio, Kuopio,
Finland, 3Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland, 4Department of Public Health, School of Public Health and Clinical Nutrition,
University of Kuopio, Kuopio, Finland, 5Information Technology Centre, University of Kuopio, Kuopio, Finland, 6Department of Clinical Physiology and Nuclear Medicine,
Kuopio University Hospital, Kuopio, Finland
Abstract
Background: The evidence of the multiple beneficial health effects of fish consumption is strong, but physiological
mechanisms behind these effects are not completely known. Little information is available on the effects of consumption of
different type of fish. The aim of this study was to investigate how fatty fish or lean fish in a diet affect serum lipidomic
profiles in subjects with coronary heart disease.
Methodology and Principal Findings: A pilot study was designed which included altogether 33 subjects with myocardial
infarction or unstable ischemic attack in an 8-week parallel controlled intervention. The subjects were randomized to either
fatty fish (n=11), lean fish (n=12) or control (n=10) groups. Subjects in the fish groups had 4 fish meals per week and
subjects in the control group consumed lean beef, pork and chicken. A fish meal was allowed once a week maximum.
Lipidomics analyses were performed using ultra performance liquid chromatography coupled to electrospray ionization
mass spectrometry and gas chromatography. Multiple bioactive lipid species, including ceramides, lysophosphatidylcho-
lines and diacylglycerols, decreased significantly in the fatty fish group, whereas in the lean fish group cholesterol esters and
specific long-chain triacylglycerols increased significantly (False Discovery Rate q-value ,0.05).
Conclusions/Significance: The 8-week consumption of fatty fish decreased lipids which are potential mediators of lipid-
induced insulin resistance and inflammation, and may be related to the protective effects of fatty fish on the progression of
atherosclerotic vascular diseases or insulin resistance.
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Introduction
The evidence of the beneficial effects of consumption of fish and
n-3 fatty acids on coronary heart disease (CHD) mortality as well
as on cardiovascular risk factors is strong [1–3]. However, studies
on the effects of different types of fish on CHD are limited.
Controlled experimental studies have focused on the effects of
supplemental n-3 long-chain polyunsaturated fatty acids (PUFA)
rather than the effects of different types of fish consumption. Fatty
acid content varies a lot between different fish species and
depending on the preparation method. Fatty fish intake only is
associated with increased serum concentration of n-3 long-chain
PUFA [4], thus health benefits may vary depending on the type of
fish meal consumed [5].
Epidemiological studies have shown associations between n-3
long-chain PUFA intake and insulin sensitivity [6,7], but based on
clinical trials, the evidence of positive effects on glucose metabolism
is controversial [6,8,9], favoring no effect [10,11]. However, n-3
PUFA could affect e.g. insulin receptor signaling [12,13],
inflammation [8,14–15] or cell membrane fatty acid composition
[13,16,17], which could further modulate insulin sensitivity.
Multiple bioactive lipid components may play a role behind these
mechanisms. Ceramides, for example, attenuate insulin signaling
through multiple pathways [18–20], and diacylglycerols (DG) are
identified as potential mediators of lipid-induced insulin resistance
[18,21]. Dietary exposure to eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) is observed to reduce the production
of DG and ceramides in murines [22].
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5258Here we hypothesize that specific fish diet, rich in specific
polyunsaturated fatty acids, affects not only the serum fatty acid
composition but also the concentrations of bioactive lipids. The
principal aim of the present study was to investigate how intakes of
fatty fish or lean fish affect serum lipidomic profiles in subjects with
CHD. We found that lipids related to impaired insulin signaling
and inflammation decreased after an 8-week consumption of fatty
fish, whereas this effect was not seen in the subjects who consumed
lean fish or lean meat.
Materials and Methods
The original protocol for this trial (in Finnish) and the
CONSORT checklist are available as supporting information,
Protocol S1 and Checklist S1.
Subjects
Subjects and study design for this pilot study were described in
detail by Erkkila et al [23]. In brief, altogether 44 subjects,
identified from the discharge lists of the Kuopio University
Hospital, were screened for the eligibility for the FISH -study, and
35 subjects were accepted (Figure 1). Thirty-tree of the subjects
completed the study. All of them had acute myocardial infarction
or unstable ischemic attack during the previous 3–36 months. To
be included in the study, the subjects had to have age under 70
years, normal sinus rhythm, fasting serum triglyceride concentra-
tion #3.5 mmol/l, fasting serum cholesterol concentration
#8 mmol/l, body mass index (BMI) 18.5–30 kg/m
2, fasting
plasma glucose concentration #7.0 mmol/l and they had to use
betablockers. Subjects were excluded if they used other antiar-
rhythmic medications than betablockers or psychotropic drugs,
were diagnosed with diabetes, atrial fibrillation, inflammatory
bowel disease or abnormal liver, thyroid or kidney function or
used excessive amounts of alcohol. Subjects who reported use of
fish oil supplements or high fish intakes (.3 meals/week) during
last three months were excluded from the study. All subjects were
using statins in addition to betablockers, and 88% of subjects were
using acetosalisylic acid, 45% ACE inhibitor, 39% oral anticoag-
ulant, 27% calcium antagonist and 27% nitrate as well.
Characteristics of the subjects in the intervention groups at
screening visit have been published earlier [23].
The subjects gave written informed consent for the participation
in the study. The study plan was approved by the Research Ethics
Committee, Hospital District of Northern Savo.
Study design
The study was an 8-week controlled, parallel intervention. The
subjects were randomized to one of the following groups: fatty fish
group (n=11), lean fish group (n=12) or control group (n=10).
Subjects in the fatty fish and lean fish groups were advised to
consume fish 100–150 g/meal at least four times a week. Subjects
in the fatty fish group consumed e.g. salmon, rainbow trout, Baltic
herring, whitefish and vendace, and in the lean fish group e.g.
pike, pike-perch, perch, saithe and cod. Subjects in the control
group were instructed to consume less than 1 fish meal per week
and to eat meals made with lean meat (beef or pork) or chicken
without skin. Otherwise all subjects were instructed by a clinical
nutritionist to follow a diet recommended for CHD patients [24].
They were advised to avoid sources of saturated fat like cream and
butter in food preparation. Subjects continued to use the
medications prescribed by their physicians.
Measurements were performed at baseline (week 0) and week 8.
Height, weight and blood pressure were measured and blood
samples were drawn after a 12-h overnight fast. Blood samples
drawn at baseline and week 8 were used for lipidomic and fatty
acid analyses.
Dietary intake
Subjects’ habitual dietary intake was estimated by a 4-day food
record (consecutive days, 3 weekdays and one weekend day) at the
baseline. Dietary compliance was monitored by using a 7-day food
record kept twice during the intervention (weeks 3 and 7) and with
the daily record of fish consumption. Nutrient intake was
calculated using the Micro-NutricaH dietary analysis program
(version 2.5, Finnish Social Insurance Institute, Turku, Finland).
Figure 1. The CONSORT flow diagram.
doi:10.1371/journal.pone.0005258.g001
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Blood samples were drawn from an antecubital vein. Concen-
trations of serum total, LDL and HDL cholesterol and
triglycerides (TG) were analyzed using commercial kits (981813,
981656, 981655 and 981786, respectively, Thermo Electron
Corporation, Vantaa, Finland) and Thermo Fisher Konelab
20XTi Analyzer (Thermo Electron Corporation, Vantaa, Fin-
land). Serum insulin concentration was analyzed with a chemilu-
minescent immunoassay (ACS 180 Plus Automated Chemilumi-
nescence System, Bayer Diagnostics, USA). Plasma glucose was
analyzed by using Thermo Fischer Konelab 20XTi Analyzer
(Thermo Electron Corporation, Vantaa, Finland) and kit 981779
(Thermo Electron Corporation, Vantaa).
Fatty Acid Analyses
The fatty acid method was used to measure esterified fatty acids.
The coefficient of variation of the reported method is ,1% for
each reported fatty acid.
Sample preparation. Lipids from plasma samples (50 ml)
were extracted by a mixture of chloroform and methanol (2:1,
100 ml) after addition of internal standard (20 ml,
heptadecantrienoate TG C17:0 500 mg/l+FFA C17:0 500 mg/l).
The lower layer was separated and evaporated into dryness under
nitrogen flow. The residue was dissolved into petroleumether
(700 ml, boiling point 40–60uC). Bound fatty acids were
transmethylated with NaOME (250 ml, sodium methoxide in dry
methanol0,5 M)by boiling at 45uC for 5 minutes. Themixture was
acidified by adding 15% solution of NaHSO4 (500 ml). The fatty
acidsmethylesters(FAME)andfreefattyacids(FFA)wereextracted
by petroleum ether (300 ml). The petroleumether layer containing
FAME and FFA was separated into a glass vial, evaporated under
nitrogen flow and redissolved into hexane (50 ml) and transferred
into a glass microinsert for GC analysis.
Chromatography. 2 ml aliquots were used for GC injection at
260uC. The split ratio was 1:13 and the injector liner was
deactivated with glass wool. The Agilent 5890 series II Gas
Chromatography equipped with a 25 meter HP-FFAP column
Table 1. Clinical characteristics at baseline and after the 8-week intervention (mean6SD).
Fatty fish (n=11) Lean fish (n=12) Control (n=10)
0w k 8w k P-value 0 wk 8 wk P-value 0 wk 8 wk P-value
Body mass index (kg/m2) 26.763.1 26.863.2 0.602{ 27.862.1 27.561.9 0.051 27.062.9 26.962.9 0.190
Serum cholesterol (mmol/l) 3.860.6 3.560.6 0.361 3.760.7 3.760.6 0.805 4.760.8 4.360.8 0.027
LDL cholesterol (mmol/l) 1.960.3 1.960.3 0.585 2.060.6 2.060.5 0.975 2.660.6 2.560.6 0.162
HDL cholesterol (mmol/l) 1.460.4 1.560.4 0.246{ 1.360.3 1.360.3 0.568 1.460.5 1.360.4 0.028
Serum triacylglycerols (mmol/l) 1.360.7 1.160.4 0.278 1.160.6 1.160.6 0.981{ 1.961.2 1.760.5 0.403
Plasma glucose (mmol/l) 6.160.9 6.160.5 1 5.660.4 5.560.4 0.234{ 5.760.3 5.660.3 0.185
Serum insulin (mU/l) 13.8612.4 12.368.8 0.425{ 9.765.1 8.063.8 0.175 12.667.3 11.064.7 0.392
HOMA-IR1 4.164.8 3.462.8 0.547{ 2.461.2 2.061.0 0.155 3.261.9 2.761.2 0.41{
*Paired-samples t-test.
{Logarithmic values used in statistical analyses due to the abnormal distribution.
{Wilcoxon signed ranks test used due to the abnormal distribution even after logarithmic transformation.
1HOMA-IR, HOMA insulin resistance index.
doi:10.1371/journal.pone.0005258.t001
Table 2. Daily dietary intakes at baseline and during the study (mean6SD).
Fatty fish (n=11) Lean fish (n=12) Control (n=10)
baseline
during the
study P-value* baseline
during the
study P-value* baseline
during the
study P-value*
Energy (kJ) 617961271 658661151 0.081 728661902 673861803 0.038 825163052 727361784 0.161
Total fat (E%) 31663 1 65 0.992 31642 7 64 0.003 31672 9 65 0.363
SAFA (E%) 11649 63 0.321 10638 62 0.004{ 12631 0 63 0.108
MUFA (E%) 11631 0 62 0.588{ 10619 62 0.027 10621 0 62 0.766
PUFA (E%) 6617 61 0.016{ 7616 61 0.712 5626 61 0.442{
EPA (g) 0.1360.07 0.3060.12 ,0.001 0.1560.18 0.1260.05 0.577{ 0.1160.11 0.0560.03 0.035
DHA (g) 0.3160.19 0.7760.29 0.001 0.3660.54 0.3260.10 0.219{ 0.2460.25 0.1160.08 0.077
a-linolenic acid (g) 1.460.7 1.960.8 0.028{ 1.760.8 1.660.6 0.49 1.460.8 1.560.7 0.421{
Linoleic acid (g) 6.562.2 8.361.9 0.065 8.063.6 7.563.0 0.40 9.0766.8 7.463.6 0.602{
Values at baseline are based on a 4-day food records, and values during the study are based on a 7-day food records kept twice during the study.
*Paired-samples t-test.
{Logarithmic values used in statistical analyses due to the abnormal distribution.
doi:10.1371/journal.pone.0005258.t002
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totalflow of30 ml/min.Theinitial oven temperaturewas70uCan d
the temperature was increased at rate of 7uC/min until 240uC. The
fatty acids were detected by flame ionization detector at 300uC.
Lipidomic analyses
Lipidomics analyses were performed as described earlier [25].
In brief, plasma samples (10 ml) were diluted with 10 ml sodium
chloride (0,9%) and 20 ml of an internal standard mixture
containing 10 lipid classes. The lipids were extracted with
chloroform/methanol (2:1, 100 ml). An external standard mixture
containing 3 labeled standards (10 ml) was added to the lipid
extracts. Half of the lipid extract was transferred into another
HPLC vial as a replicate. The sample order for LC/MS analysis
was determined by randomization.
Ultra performance liquid chromatography coupled to
electrospray ionization mass spectrometry (UPLC-ESI-
MS). Lipid extracts were analyzed on a Waters Q-Tof Premier
mass spectrometer combined with an Acquity Ultra Performance
Liquid chromatography. The column was an Acquity
UPLC
TMBEH C18 1650 mm with 1.7 particles. The binary
solvent system includes A. water (1% 1 M NH4Ac, 0.1%
HCOOH) and B. isopropanol:acetonitrile (1:2.5, 1% 1 M
NH4Ac, 0,1% HCOOH). The gradient started from 65% A/
35% B and reached 100% B in 6 minutes and remains at this level
for next 7 minutes. The flow rate was 200 ml/min and the
injection volume was 1 ml. The profiling of lipid extracts was
carried out on Waters Q-Tof premier mass spectrometer using
ESI+ mode. The voltages of the sampling cone and capillary were
45.0 V and 2.9 kV, respectively. The source temperature was set
at 120uC and nitrogen was used as desolvation gas (795 L/h) at
270uC. The data were collected in centroid mode at mass range of
m/z 300–1200 with a scan time of 0.20 sec. Reserpine (50 ml/L)
was used as the lock spray reference compound at a flow rate of
10 ml/min and the scan was done at 10 s frequency.
Data processing. Data processing was performed using
MZmine software version 0.60 [26]. MZmine processing consisted
of four phases: 1) peaks detection, 2) aligning based on retention times
and m/z values, 3) filtering out peaks appearing only few samples and
4) gap filling. The quality of results was controlled by checking that
Table 3. Plasma fatty acids (%) at baseline and after the 8-week intervention (mean6SD).
Fatty fish (n=11) Lean fish (n=12) Control (n=10)
0w k 8w k P-value 0 wk 8 wk P-value 0 wk 8 wk P-value
Myristic acid (14:0) 0.7360.41 0.7260.32 0.996{ 0.6560.41 0.6360.26 0.71{ 0.9260.40 0.8360.28 0.30
Palmitic acid (16:0) 24.4662.29 23.7361.78 0.250 24.3661.95 24.0061.26 0.51 24.8461.85 24.1161.70 0.11
Palmitoleic acid (16:1n-7) 2.2861.14 2.0660.75 0.270 2.1760.63 2.1060.69 0.69 2.6761.11 2.6360.91 0.83
Stearic acid (18:0) 8.3360.99 8.5161.07 0.390 8.1460.95 8.1461.08 0.98 7.7660.96 7.4560.73 0.31
Oleic acid (18:1n-9) 22.6863.72 20.1163.64 0.009 21.6162.61 22.2463.25 0.50 26.2265.05 26.6462.87 0.70
Cis-vaccenic acid (18:1n-7) 2.3860.32 2.3660.33 0.680 2.3860.30 2.4860.37 0.04 2.6260.46 2.6860.50 0.54
Linoleic acid (18:2n-6) 19.8563.55 19.9261.96 0.920 21.1661.49 21.1062.75 0.94 18.7364.53 19.7864.89 0.14
c-linolenic acid (18:3n-6) 0.6060.32 0.6360.34 0.82{ 0.5260.32 0.4860.21 0.57 0.4660.19 0.5260.19 0.28
a-linolenic acid (18:3n-3) 1.0360.40 1.2060.41 ,0.001{ 1.0460.31 1.0760.29 0.55 1.0860.37 1.2160.37 0.18
Di-homo-c-linolenic acid (20:3n-6) 1.9260.42 1.6260.39 0.005 1.8260.34 1.8560.33 0.74 1.6360.35 1.6760.27 0.73
Arachidonic acid (20:4n-6) 7.8161.73 7.1861.61 0.140 8.0861.45 8.1461.70 0.64{ 6.8861.50 7.0460.85 0.68
Eicosapentaenoic acid (20:5n-3) 2.4160.71 4.6562.02 ,0.001{ 2.5261.11 2.1561.10 0.27{ 1.9861.38 1.5460.58 0.37{
Docosapentaenoic acid (22:5n-3) 0.9760.15 1.1460.17 0.016 1.0260.23 0.9660.31 0.07{ 0.8760.21 0.8560.17 0.77
Docosahexaenoic acid (22:6n-3) 4.5360.80 6.1561.17 0.001 4.5361.47 4.6961.86 0.72 3.3461.67 3.0360.80 0.43
*Paired samples t-test.
{Logarithmic values used in statistical analyses due to the abnormal distribution.
{Wilcoxon signed ranks test used because the distribution of variance was not normal even after logarithmic transformation.
doi:10.1371/journal.pone.0005258.t003
Figure 2. False Discovery Rate q-values based on one-way
ANOVA test for each of the 307 identified lipids (represented
by black dots) from the lipidomics dataset across the three
intervention groups at baseline (horizontal axis) and after the
8 week intervention (vertical axis). None of the lipids reached
q,0.05 at baseline.
doi:10.1371/journal.pone.0005258.g002
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LipidName q-value* q-value* P{ (8 wk) P{ (8 wk) P{ (8 wk) Within-person q-value{ Within-person q-value{
0w k 8w k
Fatty fish vs.
Control
Lean fish
vs. Control
Fatty vs.
Lean fish
log2 Fold
Fatty fish Fatty fish
log2 Fold
Lean fish Lean fish
Cer(d18:1/23:0) 0.32 0.0163 0.0060 0.3629 0.1438 0.72 0.0316 1.14 0.3434
Cer(d18:1/24:1) 0.15 0.0112 0.0100 0.1179 0.2048 0.79 0.0418 1.30 0.1861
ChoE(20:5) 0.15 0.0014 0.0069 0.7417 0.0022 2.48 0.0145 1.53 0.0450
DG(32:5) 0.33 0.0116 0.0126 0.2925 0.0406 0.70 0.0350 0.93 0.2367
DG(40:1) 0.41 0.0163 0.0242 0.9314 0.0278 0.71 0.0431 0.96 0.2776
DG(44:7) 0.33 0.0231 0.0464 0.7112 0.0488 0.69 0.0340 1.00 0.3416
PC(32:0) 0.53 0.0092 0.0112 0.4808 0.0183 0.81 0.0431 1.11 0.4004
PC(32:3) 0.34 0.0137 0.0165 0.9481 0.0244 0.64 0.0046 1.10 0.4318
PC(34:1) 0.18 0.0016 0.0009 0.0135 0.0937 0.80 0.0340 1.27 0.2251
PC(34:2) 0.25 0.0074 0.0060 0.1091 0.1285 0.80 0.0340 1.21 0.2387
PC(34:3) 0.52 0.0157 0.0360 0.8519 0.0094 0.60 0.0346 2.30 0.3328
PC(36:0) 0.30 0.0194 0.0323 0.3009 0.1201 0.76 0.0219 1.00 0.3821
PC(36:2) 0.18 0.0131 0.0283 0.0766 0.3837 0.83 0.0285 1.28 0.1559
PC(36:4) 0.15 0.0026 0.0007 0.0694 0.0466 0.75 0.0145 1.31 0.1179
PC(36:5) 0.27 0.0007 0.0031 0.7644 0.0005 1.59 0.0219 1.18 0.2147
PC(38:4) 0.14 0.0148 0.0201 0.1403 0.2482 0.76 0.0144 1.34 0.1387
PC(38:6) 0.33 0.0007 0.0000 0.0147 0.0272 0.78 0.0219 1.34 0.2222
PC(38:8) 0.24 0.0227 0.0289 0.8910 0.0598 0.73 0.0215 1.01 0.3821
PC(40:6) 0.20 0.0061 0.0017 0.0671 0.1738 0.79 0.0092 1.47 0.1324
PC(32:0e) 0.15 0.0299 0.0619 0.2177 0.4420 0.85 0.0405 1.11 0.2511
PC(32:1e) 0.15 0.0282 0.1302 0.0546 0.9694 0.80 0.0260 1.08 0.3434
PC(34:0e) 0.43 0.0074 0.0055 0.2738 0.0460 0.74 0.0340 0.99 0.3434
PC(34:3e) 0.30 0.0502 0.1275 0.4267 0.3502 0.87 0.0470 1.25 0.1731
PC(36:5e) 0.29 0.0168 0.0301 0.2182 0.1671 0.81 0.0431 1.19 0.2519
PC(36:5e) 0.29 0.0215 0.0333 0.2221 0.2432 0.82 0.0431 1.15 0.3416
PC(38:5e) 0.28 0.0073 0.0075 0.0464 0.2917 0.80 0.0418 1.19 0.3328
PC(38:6e) 0.27 0.0292 0.0437 0.6380 0.1409 0.75 0.0418 1.05 0.4004
PC(40:4e) 0.15 0.0519 0.0867 0.2897 0.6964 0.80 0.0340 1.05 0.4137
PE(32:1) 0.33 0.0225 0.0409 0.5987 0.0428 0.73 0.0336 1.11 0.4004
PE(34:3e) 0.45 0.0049 0.0027 0.1297 0.0424 0.80 0.0442 1.15 0.3699
PE(36:2e) 0.48 0.0030 0.0021 0.0576 0.0407 0.69 0.0260 1.07 0.4004
PE(36:5e) 0.52 0.0040 0.0051 0.1544 0.0144 0.85 0.0418 1.06 0.3254
PE(36:6e) 0.33 0.0028 0.0358 0.2720 0.0006 1.29 0.0340 1.10 0.4004
PE(38:5e) 0.33 0.0013 0.0004 0.0482 0.0088 0.80 0.0431 1.25 0.1221
PS(32:0) 0.42 0.0148 0.0254 0.6437 0.0202 0.74 0.0486 1.21 0.4191
lysoPC(16:0) 0.31 0.0167 0.0620 0.0413 0.8165 0.86 0.0219 1.07 0.4321
lysoPC(16:1) 0.35 0.0226 0.0665 0.0808 0.6391 0.80 0.0219 1.03 0.3821
lysoPC(18:0) 0.28 0.0416 0.2450 0.1176 0.6576 0.84 0.0291 1.11 0.4237
lysoPC(18:0e) 0.33 0.0217 0.0333 0.7159 0.0736 0.70 0.0291 1.00 0.3821
lysoPC(18:1) 0.34 0.0148 0.0318 0.0458 0.6183 0.78 0.0260 1.04 0.4004
lysoPC(18:1e) 0.47 0.0176 0.0435 0.0728 0.5809 0.75 0.0046 0.87 0.1308
lysoPC(18:2) 0.48 0.0585 0.1557 0.5233 0.3675 0.80 0.0316 1.01 0.3821
lysoPC(18:2e) 0.32 0.0384 0.1048 0.2481 0.5073 0.79 0.0260 1.09 0.4364
lysoPC(20:3) 0.25 0.0028 0.0005 0.1476 0.0331 0.69 0.0219 1.11 0.3434
lysoPC(20:4) 0.33 0.0316 0.0502 0.3135 0.3082 0.73 0.0219 1.03 0.4004
lysoPE(19:2e) 0.40 0.0157 0.0366 0.0576 0.6570 0.85 0.0219 1.03 0.4042
lysoPE(20:0e) 0.28 0.0058 0.0038 0.1484 0.0429 0.60 0.0101 0.90 0.2045
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were performed as follows: all monoacyl lipids except cholesterol
esters, such as monoacyl-glycerophospholipids, were normalized with
lysophosphatidylcholine PC(17:0/0:0) internal standard, all diacyl
phosphocholines and SMswere normalized with phosphatidylcholine
PC(17:0/17:0), the diacyl ethanolamine phospholipids were
normalized with phosphatidylethanolamine PE(17:0/17:0), the
diacyl phosphoserine phospholipids were normalized with
phosphatidylserine PS(17:0/17:0), the diacyl phosphates and
phosphoglycerols were normalized with phosphatidic acid PA(17:0/
17:0), and the triacylglycerols and cholesterol esters with
triacylglycerol TG(17:0/17:0/17:0). Unidentified species were
normalized by PC(17:0/0:0) for retention time ,300 seconds,
PC(17:0/17:0) for the retention time between 300 s and 410 s, and
TG(17:0/17:0/17:0) for higher retention times.
Statistical analyses
Biochemical data were statistically analyzed using the SPSS
statistical software (version 14.0, SPSS Inc., Chicago, IL) and R
software version 2.4.1 [27]. The data are expressed as mean6SD.
Fold changes for the lipids were calculated dividing the endpoint
values by the baseline values. The HOMA insulin resistance index
(HOMA-IR) was calculated as following: fP-Insulin (mU/l)6fP-
Glucose (mmol/l)/22.5. The normality of distributions of the
variables was tested with the Kolmogorov-Smirnov test with
Lilliefors significance correction. The variables with abnormal
distribution were normalized with logarithmic transformation or a
non-parametric test was used if normal distribution was not
achieved with transformation. Paired samples t-test or Wilcoxon
signed ranks test was used when comparing baseline and endpoint
values within the groups. Spearman rank correlation was used to
calculate correlation coefficients. P-values ,0.05 were considered
significant. For the high-dimensional lipidomics dataset, the P-
values were corrected for multiple comparisons by calculating the
False Discovery Rate (FDR) q-values [28]. In order to compare the
group differences at baseline and after the intervention, one-way
analysis of variance (ANOVA) was performed on lipidomics data
for each lipid separately at baseline and after the intervention. The
FDR q-values were also calculated from the ANOVA P-values. q-
values ,0.05 were considered significant.
Mixed model was used to assess relation between lipidomics
variables and sum of EPA and DHA. Due to the skewness of the
variables (both dependent variables and sum of DHA and EPA)
they were transformed to logarithmic scale. And after that they
were standardized (to have zero mean and standard deviation of 1)
in order to get comparable (or standardized) regression coefficients
of mean variable for dependent variables. Every transformed
lipidomics variable was modeled by an own model with
transformed mean variable and time as a fixed and person as a
random explanatory variables. In order to correct for multiple
comparisons, FDR q-values are reported in addition to P-values.
Results
Clinical characteristics and dietary intake
Clinical characteristics at baseline and after the intervention are
presented in Table 1. There were no significant changes in the
fatty or lean fish groups. In the control group, serum total and
HDL cholesterol concentrations decreased (P=0.027 and 0.028,
respectively) during the intervention. The use of medications did
not differ among the groups [23].
Self-reported compliance with the diet was good. Average fish
consumption during the study was 4.3, 4.7 and 0.6 fish meals per
week in the fatty fish, lean fish and control groups, respectively.
Nutrient intake at baseline and during the study was reported
earlier in detail [23]. In the fatty fish group the dietary intake of
total PUFA, EPA, DHA and a-linolenic acid increased (Table 2).
In the lean fish group, the intakes of total energy, total fat as well as
SAFA, PUFA and MUFA decreased. In the control group, the
intake of EPA decreased during the intervention.
LipidName q-value* q-value* P{ (8 wk) P{ (8 wk) P{ (8 wk) Within-person q-value{ Within-person q-value{
0w k 8w k
Fatty fish vs.
Control
Lean fish
vs. Control
Fatty vs.
Lean fish
log2 Fold
Fatty fish Fatty fish
log2 Fold
Lean fish Lean fish
TG(51:2) 0.41 0.0148 0.0021 0.1537 0.3702 0.72 0.0409 1.29 0.4067
TG(52:2) 0.15 0.0007 0.0004 0.0021 0.3932 0.77 0.0489 2.08 0.1279
TG(53:2) 0.15 0.0008 0.0002 0.0028 0.3282 0.74 0.0431 1.57 0.2511
TG(54:1) 0.45 0.0083 0.0086 0.1742 0.0464 0.72 0.0431 1.14 0.3989
TG(54:2) 0.23 0.0007 0.0004 0.0013 0.4665 0.73 0.0431 1.74 0.1861
TG(55:3) 0.29 0.0023 0.0003 0.0139 0.2370 0.75 0.0486 1.35 0.3821
TG(56:4) 0.15 0.0042 0.0013 0.0739 0.1085 0.72 0.0418 1.71 0.1869
TG(56:5) 0.15 0.0007 0.0002 0.0004 0.5019 0.74 0.0405 1.88 0.1005
TG(56:7) 0.15 0.0327 0.3281 0.3476 0.0662 1.63 0.1218 1.97 0.0450
TG(56:8) 0.15 0.0062 0.0282 0.9410 0.0180 2.24 0.0662 1.82 0.0439
TG(58:8) 0.14 0.0163 0.1217 0.5548 0.0275 1.60 0.1155 1.98 0.0439
TG(58:9) 0.15 0.0058 0.0180 0.8328 0.0151 1.86 0.0763 1.75 0.0481
Since 240 lipids reached q,0.05 at 8 weeks based on one-way ANOVA across the three groups, additional criteria were applied to limit the number of lipids for clarity.
Only lipids with within-person changes in Lean or Fatty fish group significant at q,0.05 are included. No lipids were changed significantly within the Control group. For
isobaric lipid species of the same class, total number of carbons and double bonds, only one specie with the highest mean concentration is listed.
*FDR q-values calculated from P-value distribution obtained from one-way ANOVA.
{Two-sided t-test.
{FDR q-values calculated from P-value distribution obtained from paired samples t-test.
doi:10.1371/journal.pone.0005258.t004
Table 4. cont.
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Proportions of plasma oleic acid (18:1n-9) and dihomo-c-
linolenic acid (20:3n-6) decreased and those of a-linolenic (18:3n-
3), arachidonic (20:4n-6), EPA (20:5n-3), docosapentaenoic (22:5n-
3) and DHA (22:6n-3) increased in the fatty fish group (Table 3).
In the lean fish group, only the proportion of cis-vaccenic acid
(18:1n-7) increased. No significant changes in plasma fatty acids
were observed in the control group.
A total of 307 lipids were identified and quantified by the
UPLC/MS lipidomics platform. We first established that there
were no significant lipid changes between the groups at baseline
(Figure 2). A total of 240 lipids were different across the three
Figure 3. Bar charts of fold changes for different lipid classes (calculated as a sum of lipid concentrations within a class) in each
group. *, P,0.05; **, P,0.01; ***, P,0.001. P-values were calculated using paired samples t-test (differences inside the groups before and after
intervention).
doi:10.1371/journal.pone.0005258.g003
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comparing within-person changes across the three intervention
groups, no lipids were significantly altered in the control group,
while 63 and 5 lipids changed in the fatty and lean fish groups,
respectively (Table 4). Multiple bioactive lipid species, including
ceramides, lysophosphatidylcholines (lysoPC), DGs, phosphatidyl-
cholines and lysophosphatidylethanolamines, decreased signifi-
cantly in the fatty fish group, whereas in the lean fish group
cholesterol esters and specific long-chain triacylglycerols increased
significantly (Table 4 and Figure 3).
The mixed model revealed that the plasma contents of EPA and
DHA were strongly correlated with the plasma long chain TG,
cholesterol ester and lysoPC with EPA bound (ChoE(20:5) and
lysoPC(20:5)), and with specific phosphatidylcholines (Table 5).
They were also significantly related with the ether bonded
phosphatidylethanolamines (plasmalogens) (Table 5).
Discussion
We investigated the effect of fatty fish, lean fish or lean meat
intake on plasma lipidomic profile in individuals with CHD. We
found that the 8-week consumption of fatty fish altered the
lipidomic profile markedly, while the lean fish or control diet did
not cause such changes. Interestingly, the serum lipids found
affected by the fatty fish diet are associated with insulin signaling
and inflammation [19–21,29,30].
Fatty acid analysis revealed the increases in plasma content of all
long chain n-3 fatty acids in the fatty fish group, which confirms the
good compliance to the diet. The subjects wereinstructed to use low
erucic acid rapeseed oil based liquid margarines or vegetable oils
(rapeseed oil most commonly used in Finland) for frying the fish,
which increased the intake of ALA during the study.
Based on food records, the total energy intake decreased
significantly in the lean fish group. However, there were no
significant changes in their weight or body mass index. In the
control group, the intake of EPA decreased during the
intervention, but no changes in plasma fatty acids were seen in
this group. The fish consumption was restricted to one fish meal
per week in the control group, which was less than subjects
habitually consumed. Seventy % of the control subjects consumed
habitually 1–2 fish meals per week and 30% consumed less than
one fish meal per week.
The principal findings of the present study, as revealed by the
lipidomic analysis, were diminished DGs, ceramides and lysoPCs
in the fatty fish group (Table 4 and Figure 3). DG is the potential
mediator of lipid-induced insulin resistance via activation of novel
protein kinase C (nPKC), which inhibits insulin action and is also
related to inflammatory response [18,21]. Ceramides are suggest-
ed to attenuate insulin signaling through multiple pathways, but
the exact mechanism is not completely known [18–20,31].
Suggested mechanisms include protein phosphatase-2A (PP2A)
activation and inactivation of Akt/ Protein kinase B (PKB), which
attenuate the insulin response [18,31]. Our results of decreased
plasma DG and ceramide content due to high dietary intake of n-3
fatty acids in the fatty fish group are consistent with the
observations that dietary exposure to EPA and DHA reduce DG
and ceramide production in murines [22]. Taken together, these
results and the fact that the prevalence of impaired glucose
tolerance and type 2 diabetes is lower in populations consuming
large amounts of n-3 fatty acids, supports the concept that DG and
ceramides may be the link between n-3 fatty acids and insulin
resistance.
We also found a decrease in lysoPC in the fatty fish group,
which may be related to anti-inflammatory effects of n-3 fatty acids
[8]. LysoPC is the major bioactive lipid component of oxidized
LDL and may be responsible for many of the inflammatory effects
of oxidized LDL [29,30]. As expected, EPA and DHA were
related with the plasma long chain TG as well as EPA bound
cholesterol ester and lysoPC. They were also related significantly
with the plasmalogens, the endogenous antioxidants [32], which
can be explained by a high affinity of EPA and DHA for acylation
to the sn-2 position of plasmalogen phospholipids [33].
All subjects were using multiple medications, which may have
confounded the possible effects of fish consumption. However, it is
not possible to study the selected study population without
numerous medications. All subjects were using statins, which are
known to cause drug-specific changes in the plasma lipidomic
profile [34].
In conclusion, this study indicates that the 8-week consumption
of fatty fish decreased plasma lipids which are potential mediators
of lipid-induced insulin resistance and inflammation, and may be
related to the protective effects of fatty fish on the progression of
CHD or insulin resistance. Future studies are needed to find out if
these bioactive lipid components are changed due to fish
consumption in other tissues, like in skeletal muscle, adipose tissue
or immune cells as well.
Table 5. Lipids related with plasma content of sum of EPA
and DHA based on mixed model.
Lipids Coefficient
Standard
error P-value FDR q-value
ChoE(20:5)* 0.52 0.09 0.001 0.001
lysoPC(20:5){ 0.58 0.11 0.001 0.001
PC(36:5){ 0.56 0.10 0.001 0.001
PC(38:5) 0.38 0.12 0.003 0.026
PC(38:6e) 0.34 0.12 0.009 0.068
TG(60:11)1 0.46 0.12 0.001 0.009
TG(58:9) 0.42 0.11 0.001 0.013
TG(58:8) 0.42 0.11 0.001 0.013
TG(58:10) 0.42 0.12 0.001 0.016
TG(57:8) 20.41 0.12 0.001 0.017
TG(56:8) 0.39 0.11 0.001 0.017
TG(54:1) 20.39 0.12 0.002 0.026
TG(59:13) 0.37 0.12 0.003 0.026
TG(58:8) 0.37 0.12 0.004 0.032
TG(52:0) 20.36 0.12 0.004 0.032
TG(40:3) 20.34 0.12 0.007 0.056
TG(51:2) 20.34 0.12 0.008 0.056
TG(56:9) 0.34 0.12 0.009 0.056
PE (38:5e)
a 20.33 0.13 0.014 0.067
PE (36:6e) 0.31 0.13 0.020 0.068
PE(36:2e) 20.26 0.12 0.037 0.074
PE(42:1e) 0.27 0.13 0.044 0.076
Lipids with P-value ,0.001 and phosphatidylethanolamines (plasmalogens)
with P-value ,0.05 reported.
*ChoE, Cholesterol ester.
{lysoPC, lysophosphatidylcholine.
{PC, phosphatidylcholine.
1TG, triacylglycerol.
aPE, phosphatidylethanolamine.
doi:10.1371/journal.pone.0005258.t005
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